Side-by-side · Research reference

DSIPvsTesofensine

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticDraft8/36 cited

BPhase 3Draft10/40 cited

DSIP

Sleep modulator · Anti-stress

100–200 mcgPer doseSchneider 1986

HumanMechanisticSchneider 1986

HoursHalf-life (est)

SQ · Pre-sleep · Daily during cycle

Tesofensine

SNDRI · Phase 3 obesity candidate

0.25–0.5 mgDaily doseAstrup 2008

9.2 kgWeight ↓ (24 wk)Astrup 2008

Phase 3Evidence levelAstrup 2008

Oral · Once daily morning

01Mechanism of Action

Parameter

DSIP

Tesofensine

Primary target

Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986

Serotonin / norepinephrine / dopamine transporters (SERT / NET / DAT)Astrup 2008

Pathway

Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986

Triple monoamine reuptake inhibition → ↑synaptic 5-HT, NE, DA → appetite suppression + thermogenesisAstrup 2008

Downstream effect

Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986

Strong appetite suppression, mild thermogenic effect, weight lossAstrup 2008

Feedback intact?

—

Origin

Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986

Small molecule developed by NeuroSearch (Denmark) for CNS indications, repurposed for obesityAstrup 2008

Antibody development

—

02Dosage Protocols

Parameter

DSIP

Tesofensine

Standard dose

100–200 mcg SQ pre-sleepSchneider 1986

0.25–0.5 mg / dayAstrup 2008

Frequency

Once daily, pre-sleep

Once daily, morning

Lower / starter dose

50 mcg pre-sleep

0.125 mg / day

Evidence basis

Human-mechanistic + early clinicalSchneider 1986

Phase 2b + ongoing Phase 3Astrup 2008

Duration

8–12 weeks per cycle

24 weeks per studied cycle

Reconstitution

Bacteriostatic water

—

Timing

30–60 min pre-sleep

Morning to avoid sleep disruption

Half-life

Short plasma; CNS effects last hours

~9 days (very long)

Form

—

Oral capsule

04Side Effects & Safety

Parameter

DSIP

Tesofensine

Injection site reaction

Mild irritation

—

Drowsiness

Expected effect (intentional)

—

Vivid dreams

Anecdotally reported

—

Long-term safety

Limited modern RCT data

—

Pregnancy / OB

Avoid

Contraindicated

Heart rate / BP

—

Dose-dependent ↑ HR + BPAstrup 2008

Insomnia

—

Dose-related; mitigate with morning timing

Dry mouth

—

Common

Nausea

—

Common

Mood changes

—

Anxiety / agitation possible

Cardiovascular events

—

Phase 3 trial monitoring; not yet FDA-cleared

Absolute Contraindications

DSIP

·Pregnancy / breastfeeding
·Concurrent CNS-depressant therapy without supervision

Tesofensine

·Pregnancy / breastfeeding
·Severe cardiovascular disease
·Concurrent MAOI use

Relative Contraindications

DSIP

·Severe sleep apnoea (untreated)
·Concurrent benzodiazepine / opioid use

Tesofensine

·Hypertension
·Anxiety disorder
·Insomnia

05Administration Protocol

Parameter

DSIP

Tesofensine

1. Reconstitution

Add 1–2 mL bacteriostatic water to vial.

Oral capsule (investigational; not commercial).

2. Injection site

SQ — abdomen. Rotate sites.

Swallow whole with water, morning only.

3. Timing

30–60 min pre-sleep.

Morning to mitigate insomnia. Do not dose evening.

4. Storage

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

Room temp ≤25 °C, dry place.

5. Needle

29–31G insulin syringe.

Monitor BP + HR + mood. Avoid stimulants + MAOIs.